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Patients with primary immunodeficiency disorders (PID) have an increased risk from acute
and chronic Epstein–Barr Virus (EBV) viral infections and EBV-associated malignancies.
Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients
with PID, but EBV-related complications are common in the immediate post-transplant
period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with
EBV-specific T cells is a promising therapeutic strategy for patients with PID both before
and after HSCT. Here we review the methods used to manufacture EBV-specific T cells,
the clinical outcomes, and the ongoing challenges for future development of the strategy.
Keywords: primary immunodeficiency disorders, Epstein–barr virus, adoptive T cell therapy, immunotherapy,
hematopoietic stem cell transplantation

BACKGROUND
Epstein–Barr Virus (EBV) is a herpes virus that typically causes a mild to moderate self-limiting
viral illness in healthy individuals. During primary infection, EBV establishes latency in B lymphocytes and oral epithelial cells. The level of B lymphocytes latently infected is maintained at a very
low level through a potent cell-mediated immune response by EBV-specific T lymphocytes (1).
However, individuals with moderate to severe forms of primary immunodeficiency disorders (PID)
have weakened T-cell immunity with diminished immunosurveillance. PID patients are at risk
from EBV-related complications which include acute and chronic infections and EBV-associated
malignancies. EBV is also a frequent inciting factor for hemophagocytic lymphohistiocytosis (HLH)
in PID with impaired cell-mediated cytotoxicity.
Hematopoietic stem cell transplantation (HSCT) has been used as curative approach for severe
combined immunodeficiency (SCID) for over 50 years, and the approach is increasingly being used
for other PIDs (2, 3). However, reconstitution of T cell immunity, needed to control both acquired
viral infections reactivating viruses, is delayed for up to 6 months after transplantation. During
this period patients remain extremely vulnerable to viral complications. While antiviral pharmacotherapy is available for many of the viruses that contribute to pre- and post-HSCT morbidity
and mortality, their use is limited by toxicities and emerging resistance. Rituximab, a monoclonal
antibody targeting CD20, has good efficacy against EBV. However, Rituximab targets not only the
EBV-infected B cells, but also the healthy B cell compartments, which further weakens the immune
system. Resistance to rituximab has also been described (4). Given these limitations, adoptive
therapy with EBV-specific T cells has emerged as a promising therapeutic strategy for PID patients
with EBV-related complications.
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Adoptive therapy with viral-specific T cells (VSTs) has been
used for over 20 years (5, 6). Earliest experience using cellular
therapy for EBV-related post-transplant lymphoproliferative
disease (PTLD) after HSCT included using unmanipulated donor
lymphocyte infusions, which was often effective, but carried a
high risk of graft-versus-host disease (GVHD) (7). Subsequently,
VSTs have been developed that show safety and efficacy in treating EBV infections while minimizing the risk of GVHD (8–13).
While previous reviews have primarily examined the use of all
forms of VSTs for patients with PID (14, 15), this review focuses
specifically on the development of and clinical use of EBV-specific
T cells for patients with PID.

clinical use. While IFN-γ capture is not HLA-restricted and
produces a polyclonal and polyfunctional product containing
CD4+ and CD8+ T cells, multimer selection is an HLA-restricted
process, and generally yields only CD8+ T cells.

PREVIOUS CLINICAL USAGE OF EBVSPECIFIC T CELLS FOR PID DISORDERS
Donor-Derived EBV-Specific T Cells

As PID is one of the most common non-malignant indications
for referral to HSCT in pediatrics and is associated with high
risk for viral complications, patients with PID constitute a
sizeable proportion of patients in VST clinical trials (Table 1).
A large, multi-center study with a median follow-up of 10 years
treated 114 patients with EBV-specific T cells after HSCT, either
for prophylaxis (n = 101) or treatment (n = 13) and included
13 patients with PID. All patients treated as prophylaxis had
no subsequent EBV viremia, while three patients with active
disease attained a complete response (CR) and three additional
patients achieved a PR (10). Papadopoulou et al. included four
patients with PID in their clinical trial of multivirus-specific
T cells (CMV, EBV, AdV, HHV6, BK), two of whom received
T cells for EBV-related complications and both of whom
obtained a CR (20).
In a large retrospective review of 36 PID patients receiving
VSTs, Naik et al. included four patients with IL2RG-SCID as
well as patients with Wiscott–Aldrich and combined immunodeficiency disorder (CID) who received donor-derived-specific
T cells for prophylaxis. All patients remained free of EBV viremia
after receiving T cells (14). Additionally, one patient with HLH
received donor-derived trivirus VSTs (CMV, EBV, Adv) for CMV
and EBV viremia with clearance of both viruses.

EBV-SPECIFIC T CELL GENERATION
METHODS
Several methods have been developed to generate EBV-specific
T cell products with minimally alloreactive T cells to decrease
the risk of GVHD. These techniques include ex vivo expansion,
multimer selection, and IFN-γ capture. To date, ex vivo expansion
is the most commonly used method.
Many ex vivo expansion methods use EBV-transformed
lymphoblastoid cell lines (LCL) as antigen presenting cells
(APCs). LCLs are advantageous APCs as they express all 10 EBV
latency antigens (type III latency), but also high levels of class I
and II HLA and co-stimulatory molecules (16). Either activated
monocytes or dendritic cells are used in the first stimulation,
with LCLs used for subsequent stimulations. To further refine
this technique, groups have developed methods for modifying
LCL by either pulsing with synthetic peptide pools encompassing
viral antigens, or transducing LCLs with adenovirus vectors that
overexpress either latent membrane protein (LMP) 2 or LMP1
and LMP2. These strategies enhance T cell specificities for the less
immunogenic EBV antigens LMP1 and LMP2 increasing their
efficacy for EBV-related lymphomas that only express LMP1 and
LMP2 (type II latency). While this method has proven to be safe
and efficacious, it takes at least 8 weeks to generate a product
suitable for clinical use as LCL take 3–4 weeks to manufacture.
This has spurred the development of rapid ex vivo culture methods using a single stimulation with APC pulsed with synthetic
peptide pools, or direct stimulation of PBMCs with synthetic
peptide pools. These methods reduce the manufacturing time to
10–14 days. Rapid ex vivo culture methods have been used for
multivirus specific T cells, but not for T cell products specific for
EBV only.
Additional techniques, such as multimer selection or IFN-γ
capture, can produce VSTs even more readily than rapid ex vivo
culture (17–19). Multimer selection uses magnetically labeled
peptide multimers to isolate T cells specific for the relevant
peptide/MHC multimers. IFN-γ capture uses an immunomagnetic separation device to isolate T cells that produce IFN-γ
when stimulated by viral antigens. Although these techniques
produce a clinical grade product within 48 h, they require
donors not only to be seropositive to the virus of interest, but
also to have a detectable level of circulating virus specific T cells.
Leukapheresis is typically needed to collect enough T cells for
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Third Party EBV-Specific T Cells

To make cellular therapy more readily available, there is growing
interest in establishing third-party banks of VSTs. Such T cell
therapeutics produced from healthy donors are available for
“off-the-shelf ” use, eliminating the time and cost associated with
custom-made products. These would be particularly beneficial
in the setting of T-cell depleted transplantation, or when EBVnaive donors are the sole option for an EBV-seropositive patient,
which would impart high risk of viral reactivation particularly in
those with prior EBV-associated disease. While there is limited
experience with third party banks to date, the results have been
promising, particularly in patients with PID (Table 2).
Vickers et al. established a large third party bank of EBVspecific T cells to treat patients with PTLD and other EBV
complications after HSCT or solid organ transplantation. To date,
they have treated three patients with PIDs, including combined
immune deficiency and chronic granulomatous disease (CGD).
One patient had a CR, but the other two died from progressive
disease (PD). At the time of publication, one additional patient
with CGD had not undergone HSCT, but had EBV-specific T cells
matched for use after transplantation (22). Two patients with CTP
synthase 1 (CTPS1) deficiency have been treated with third party
EBV-specific T cells for EBV-LPD and primary CNS lymphoma,
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Table 1 | Previous clinical use of donor-derived EBV-specific T cells.
Reference

Primary
immunodeficiency
disorders diagnosis

Indication

Specificity

Generation method

Source

Leen et al. (21)

SCID

Prophylaxis

EBV, AdV

Culture,
lymphoblastoid
cell lines (LCL) with
Ad5f35 vector

Hematopoietic stem cell
transplantation (HSCT) donor,
peripheral blood

1.35 × 108/m2

Papadopoulos
et al. (7)

GATA2 deficiency

EBV, BK

CMV, EBV,
AdV, HHV6,
BK

Culture, peptide

HSCT donor, peripheral blood

2 × 107/m2

CR

SCID variant

BK, EBV

CMV, EBV,
AdV, HHV6,
BK

Culture, peptide

HSCT donor, peripheral blood

2 × 107/m2

CR

HLH

HHV6, BK;
subsequent
EBV reactivation

CMV, EBV,
AdV, HHV6,
BK

Culture, peptide

HSCT donor, peripheral blood

1 × 107/m2

HHV6: CR; BK:
NR; EBV: CR

XLP

Prophylaxis

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

No viremia

CID

Prophylaxis

EBV

Culture, LCL

HSCT donor, peripheral blood

2.5 × 107/m2

No viremia

WAS

Prophylaxis

EBV

Culture, LCL

HSCT donor, peripheral blood

2.5 × 107/m2

No viremia

XLP

Prophylaxis

EBV

Culture, LCL

HSCT donor, peripheral blood

2

2 × 10 /m

No viremia

XLP-like

Prophylaxis

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

No viremia

WAS

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

CR

SCAEBV/NK defect

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

1 × 10 /m

CR

SCAEBV

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

PR; died of
progressive
lymphoma

SCAEBV

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

No further EBV
reactivation

XLP (SLAM mutation)

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

CR

XLP

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

PR

XLP

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 107/m2

CR
PR

Heslop
et al. (10)

Doubrovina
et al. (12)

Naik et al. (14)

Cell Dose

7

8

2

Outcomes

Alive, no active
infections

XLP

EBV viremia

EBV

Culture, LCL

HSCT donor, peripheral blood

2 × 10 /m

XLP

EBV-LPD

EBV

Culture, LCL

HSCT donor, peripheral blood

1 × 106/kg × 3
doses

PD; died

ALPS

EBV-LPD

EBV

Culture, LCL

HSCT donor, peripheral blood

1 × 106/kg

NE; died

IL2RG-SCID

Prophylaxis

CMV, EBV,
AdV

Culture, DC, and
LCL with Ad5f35fCMVpp65 vector

HSCT donor, umbilical cord

1.5 × 107/m2

No viremia

IL2RG-SCID

Prophylaxis

CMV, EBV,
AdV

Culture, DC, and
LCL with Ad5f35fCMVpp65 vector

HSCT donor, umbilical cord

2.5 × 107/m2

No viremia

IL2RG-SCID

Prophylaxis

CMV, EBV,
AdV

Culture, DC, and
LCL with Ad5f35fCMVpp65 vector

HSCT donor, umbilical cord

1 × 107/m2

No viremia

IL2RG-SCID

Prophylaxis

CMV, EBV,
AdV

Culture, DC, and
LCL with Ad5f35fCMVpp65 vector

HSCT donor, umbilical cord

1 × 107/m2

No viremia

WAS

Prophylaxis

CMV, EBV,
AdV

Culture, DC, and
LCL with Ad5f35fCMVpp65 vector

HSCT donor

1 × 107/m2

No viremia

7

2

(Continued)
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TABLE 1 | Continued
Reference

Primary
immunodeficiency
disorders diagnosis

Indication

Specificity

Generation method

Source

Cell Dose

Outcomes

CID

Prophylaxis

EBV

Culture, peptide

HSCT donor

2.5 × 107/m2

No viremia

HLH (STXBP2)

CMV, EBV

CMV, EBV,
AdV

Culture

HSCT donor

1 × 10 /m × 2
doses

WAS

Prophylaxis

CMV, EBV,
AdV

Culture

HSCT donor

2 × 107/m2

7

CMV: CR; EBV:
CR

2

No viremia

SCID, severe combine immunodeficiency; EBV, Epstein–barr virus; AdV, adenovirus; CMV, cytomegalovirus; HHV6, human herpesvirus 6; CR, complete response, HLH,
hemophagocytic lymphohistiocytosis; NR, no response; XLP, X-linked lymphoproliferative disease; CID, combined immune deficiency; WAS, Wiskott–Aldrich syndrome; SCAEBV,
severe chronic active EBV; ALPS, autoimmune lymphoproliferative syndrome; DC, dendritic cell.

Table 2 | Previous clinical use of third party Epstein–Barr Virus (EBV)-specific T cells.
Reference

Primary immunodeficiency
disorders diagnosis

Indication

Specificity

Generation
method

Source

Vickers
et al. (22)

Combined immunodeficiency
disorder (CID)

PTLD

EBV

Culture, LCL

Third party

1–2 × 106/kg/dose; 4 doses
given weekly

CR

CGD

PTLD

EBV

Culture, LCL

Third party

1–2 × 106/kg/dose; 4 doses
given weekly

PD; died

CID

PTLD

EBV

Culture, LCL

Third party

1–2 × 106/kg/dose; 4 doses
given weekly

PD; died

Wynn
et al. (23)

CTPS1 deficiency

Primary CNS
lymphoma

EBV

Culture, LCL

Third party

2 × 106/kg/dose; 7 doses given
weekly; 2 additional doses after
re-emergence of EBV disease

CR

Doubrovina
et al. (12)

Hemophagocytic
lymphohistiocytosis (HLH)

EBV-LPD

EBV

Culture, LCL

Third party

1 × 106/kg x 3 doses

CR

Naik
et al. (14)

ADA-severe combined
immunodeficiency

EBV-LPD

CMV, EBV,
AdV

Culture

Third party, prehematopoietic
stem cell
transplantation

HLH

EBV

EBV

Culture

Third party

2 × 106/kg x 3 doses

PR; died of PTLD

CTPS1 deficiency

EBV-LPD

EBV

Culture

Third party

2 × 106/kg x 2 doses

CR

SCAEBV

EBV

EBV

Culture

Third party

2 × 10 /m

Withers
et al. (24)

Cell dose

5 × 106/m2

7

2

Outcomes

NR, died from
EBV-LPD

EBV: NR; Died

CGD, chronic granulomatous disease; PTLD, post-transplant lymphoproliferative disease; PD, progressive disease; CTPS1, CTP synthase 1 deficiency; EBV-LPD,
EBV-lymphoproliferative disease; PR, partial response.

and both had CRs after T cell therapy (14, 23). Third party EBVspecific T cells have also been used in HLH as discussed below.

replacement therapy was treated with trivirus VSTs (CMV,
EBV, AdV) that were 5/10 HLA matched with the patient, but
no response was seen and the patient died of EBV-associated
lymphoma. It was unclear if VST expansion may have been
compromised in this case by the underlying inherent lymphotoxicity of ADA deficiency, as patients remain lymphopenic even
in the setting of optimal enzyme replacement therapy. However,
the patient with CTPS1 deficiency received 2 doses (2 × 10E6/
kg/dose) of 9/10 HLA match EBV-specific T cells and attained
a CR, and underwent subsequent HSCT without further viral
complications.

SPECIAL CASES
Pretransplantation

As patients with PID are particularly vulnerable to chronic and
refractory viral infections even prior to HSCT (25–27), another
benefit of third party T cells is the ability to treat patients prior
to transplant. This would not only minimize mortality associated
with transplant, but could allow more patients to be referred to
transplant. Naik et al. described two patients with PID (one with
SCID and another with CTPS1 deficiency) with partially HLAmatched third-party T cells prior to HSCT for EBV-LPD, one
of whom achieved a CR (14, 22, 23). A patient with ADA-SCID
who developed EBV viremia and CMV colitis while on enzyme
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HLH With EBV Viremia

Hemophagocytic lymphohistiocytosis is condition of hyperinflammation associated with immune dysregulation secondary
to defects in cytotoxic T lymphocyte and NK cell function.
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HLH can be either primary (associated with a known mutation) or secondary, and EBV viremia is a common trigger. In
particular, familial HLH due to mutations in STXBP2 and PRF1
have been associated with chronic EBV viremia (28). Other
PIDs have an increased risk of developing HLH, and several are
associated with EBV viremia as well as including SAP deficiency,
XIAP deficiency, ITK deficiency, and CD27 deficiency. While
EBV typically infects B cells, EBV-related HLH is frequently
associated with EBV-infected T cells, which presents therapeutic
challenges (29). As familial HLH is universally fatal without
HSCT as definitive treatment, these patients may benefit from
EBV-directed cell therapy to restore EBV-specific immunity
early after transplant.
A series of 49 patients who were treated for EBV-LPD following HSCT with donor lymphocyte infusion and/or EBV-specific
VST included three patients with PID: one with autoimmune
lymphoproliferative syndrome, one with x-linked lymphoproliferative disease, and another had primary HLH. There was an
overall response of 68% following EBV-specific VST infusion,
including a CR in the patient with HLH who received third party
EBV-specific T cells (12). Similarly, Papadopoulou et al. reported
a patient with HLH initially treated with multivirus VSTs for
HHV6 and BK viremia who subsequently developed EBV reactivation and attained complete clearance of EBV viremia without
other EBV-directed therapy after T cell infusion (20). The review
by Naik et al. included two patients with HLH and EBV viremia,
one of whom attained a CR while the other died of progressive
EBV-PTLD (14).

studies, which may in some cases relate to viral escape mutations.
In one study, a mutation in EBNA-3B enabled viral escape postT-cell therapy (31). The targeted EBV antigens differ slightly
between trials, and further studies of the lability of targeted
epitopes will be crucial to improve the efficacy of EBV-specific
T-cell therapy, particularly in the third-party setting. Best methods of partial HLA matching of third-party EBV-specific T-cells
is also unclear, particularly in the setting of rare HLA alleles that
are not known to mediate recognition of immunodominant EBV
epitopes. EBV-specific T-cells are also subject to inactivation or
killing by immunosuppressive therapies, such as corticosteroids,
which limits their use in the setting of GVHD following HCT.
Genetic modification of antigen-specific T-cells to render
them resistant to glucocorticoids and calcineurin inhibitors
may enable treatment of PTLD in spite of immunosuppressive
therapy (32, 33).
It is also unclear if adoptive T-cell therapy will be effective
prior to HCT in forms of PID in which APCs are impaired or
absent. In a recent study, defects in the costimulatory receptor
CD70 resulted in EBV-associated disease (34). CD70 defects
could theoretically impair the ability of allogeneic T-cells to lyse
infected target cells. EBV-specific T-cells have not been explored
in patients with EBV-driven HLH prior to HCT, and is unclear
whether partial restoration of cytotoxicity would be of any benefit
in this hyper-inflammatory disorder.
Currently, manufacturing of EBV-specific T-cells requires
a facility with the ability to meet regulatory guidelines for
production of immune effector cells for clinical use. Selection
methods allow make use of automated-closed systems, but
are expensive and yield low cell numbers. Ex vivo expansion yields higher cell numbers, but requires expertise in
more than minimal product manipulation. In both settings,
an EBV-seropositive donor would need to be identified for
product manufacturing. Third party T-cells circumvent these
limitations, but similarly are limited by cost of bank generation
and regulatory hurdles that limit widespread availability. New
multicenter trials using regional banks will improve accessibility to studies using EBV-specific T-cells. With the recent FDA
approval of two chimeric antigen receptor T-cell products, it is
hoped that the use of antigen-specific T-cells may similarly be
approved in the near future, enabling widespread accessibility
to these products.

Severe Chronic Active EBV

Severe chronic active EBV (SCAEBV) infection is a lymphoproliferative disorder characterized by markedly high levels of EBV in
blood and tissue that often presents with fever, lymphadenopathy,
hepatic dysfunction, and thrombocytopenia (30). In SCAEBV,
EBV can infect T and NK cells in addition to B cells. While the
etiology of SCAEBV is often unknown, the underlying defect may
represent a type of immunodeficiency. To date, HSCT has shown
to be the most effective treatment for SCAEBV. As the primary
problem in SCAEBV is an ineffective immune response to EBV,
adoptive T cell therapy with EBV-specific T cells may be very
advantageous in this patient population after HSCT. Heslop et al.
included three patients with SCAEBV (one of whom had a known
NK cell deficiency) in their trial of 114 patients receiving EBVspecific T cells. One patient was treated on the prophylactic arm
and remained free of EBV viremia. Of the two patients with active
disease at the time of T cell infusion, one patient attained a CR
while the other died of progressive EBV-associated lymphoma
(10). Withers et al. reported a patient with SCAEBV who received
third party EBV-specific T cells but died Day + 14 after infusion
of PD (24).
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